Skip to main content
Select a
location
North America
US
Canada (
EN
|
FR
)
Latin America
Brazil
Colombia
Mexico
Asia PaCific
Australia
Japan
Europe & MENA
Austria & Switzerland
Benelux
Central Eastern Europe
France
Germany
Greece
Italy
Middle East & North Africa
Nordic & Baltic countries
Russia
Spain
United Kingdom
Locations
Home
Countries: ▼
Menu utilisateur
Contact us
Foundation
Menu
About us
Our history
Rare Diseases & Orphan Drugs
Recordati
Capabilities
Manufacturing plant
Executive Management Team
Collaborations
Gender equity index
Join us
Patient focus
Acromegaly
Acute porphyria
Cushing’s Disease and Syndrome
Cutaneous T-Cell Lymphoma
Cystic Fibrosis
Homocystinuria
Homozygous Familial Hypercholesterolemia
Hyperammonaemia
HRNB
iMCD
Nephropathic cystinosis
Patent Ductus Arteriosus
Phenylketonuria
Rare Cancers
Renal Cell Carcinoma
Vitamin E deficiency in chronic cholestasis
Wilson's disease
Products
R&D
Pipeline
The Arrigo Recordati Prize
Clinical Studies
Endocrinology
Breadcrumb
Home
News
RECORDATI BOARD APPROVES THE 2023 ACCOUNTS, CONFIRMING STRONG PRELIMINARY RESULTS: REVENUE € 2,082.3M, EBITDA(1) € 769.6M, ADJUSTED NET INCOME(2) € 524.6M 2023 PROPOSED DIVIDEND € 1.20 (+4.3%)
RECORDATI BOARD APPROVES THE 2023 ACCOUNTS, CONFIRMING STRONG PRELIMINARY RESULTS: REVENUE € 2,082.3M, EBITDA(1) € 769.6M, ADJUSTED NET INCOME(2) € 524.6M 2023 PROPOSED DIVIDEND € 1.20 (+4.3%)
Twitter
Facebook
Linked in
Mail
03/19/2024
Read more
here
About us
Our history
Rare Diseases & Orphan Drugs
Recordati
Capabilities
Manufacturing plant
Executive Management Team
Collaborations
Gender equity index
Join us
Patient focus
Acromegaly
Acute porphyria
Cushing’s Disease and Syndrome
Cutaneous T-Cell Lymphoma
Cystic Fibrosis
Homocystinuria
Homozygous Familial Hypercholesterolemia
Hyperammonaemia
HRNB
iMCD
Nephropathic cystinosis
Patent Ductus Arteriosus
Phenylketonuria
Rare Cancers
Renal Cell Carcinoma
Vitamin E deficiency in chronic cholestasis
Wilson's disease
Products
R&D
Pipeline
The Arrigo Recordati Prize
Clinical Studies
Endocrinology